Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Other Non-Current Liabilities (2018 - 2025)

Regenxbio (RGNX) has 8 years of Other Non-Current Liabilities data on record, last reported at $638000.0 in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 82.45% year-over-year to $638000.0; the TTM value through Dec 2025 reached $638000.0, down 82.45%, while the annual FY2025 figure was $638000.0, 82.45% down from the prior year.
  • Other Non-Current Liabilities reached $638000.0 in Q4 2025 per RGNX's latest filing, down from $648000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $171.3 million in Q4 2021 and bottomed at $638000.0 in Q4 2025.
  • Average Other Non-Current Liabilities over 5 years is $69.0 million, with a median of $48.9 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: soared 26379.82% in 2021, then plummeted 98.38% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $171.3 million in 2021, then dropped by 19.69% to $137.6 million in 2022, then tumbled by 68.4% to $43.5 million in 2023, then plummeted by 91.64% to $3.6 million in 2024, then tumbled by 82.45% to $638000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $638000.0 in Q4 2025, $648000.0 in Q3 2025, and $664000.0 in Q2 2025.